Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

387
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
387
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

273
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
273
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

354
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
354
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

259
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
259
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.

Psychotherapy and psychosomatics·2026
Same author

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.

JAMA psychiatry·2026
Same author

An investigation into the statistical precision attainable with a distribution-free method of constructing age-dependent reference centiles.

PloS one·2025
Same author

Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.

Neuroscience applied·2025
Same author

Implications of the Co-Dominance Model for Hardy-Weinberg Testing in Genetic Association Studies.

Human heredity·2024
Same author

Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.

Urologic oncology·2023

Related Experiment Video

Updated: Apr 28, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.6K

Multivariate equivalence tests for use in pharmaceutical development.

Thomas Hoffelder1, Rüdiger Gössl, Stefan Wellek

  • 1a Boehringer Ingelheim GmbH & Co. KG , Ingelheim , Germany.

Journal of Biopharmaceutical Statistics
|June 5, 2014
PubMed
Summary

This study introduces multivariate equivalence testing for normally distributed data, extending univariate methods. These statistical techniques are crucial for establishing similarity in pharmaceutical development and manufacturing processes.

Keywords:
Delta methodDissolution profilesMahalanobis distanceMultivariate equivalence testingPrinciple intersection–unionSimilarity factorTwo-sample design

More Related Videos

Basics of Multivariate Analysis in Neuroimaging Data
06:35

Basics of Multivariate Analysis in Neuroimaging Data

Published on: July 24, 2010

17.6K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K

Related Experiment Videos

Last Updated: Apr 28, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.6K
Basics of Multivariate Analysis in Neuroimaging Data
06:35

Basics of Multivariate Analysis in Neuroimaging Data

Published on: July 24, 2010

17.6K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K

Area of Science:

  • Biostatistics
  • Pharmaceutical Sciences
  • Chemical Engineering

Background:

  • Statistical equivalence analyses are vital in biomedical research and pharmaceutical development.
  • Establishing similarity between manufacturing processes, components, or machines requires robust equivalence testing methods.
  • Existing methods often focus on univariate data, necessitating advanced techniques for complex scenarios.

Purpose of the Study:

  • To present multivariate equivalence testing procedures for normally distributed data.
  • To generalize existing univariate equivalence testing methods to multivariate settings.
  • To demonstrate the application of these methods in pharmaceutical development, specifically for dissolution profile analysis.

Main Methods:

  • Development of multivariate equivalence testing procedures.
  • Generalization of univariate equivalence testing methods.
  • Interpretation of variability as a nuisance parameter within the derived methods.
  • Application to normally distributed data.

Main Results:

  • The proposed methods provide a statistically sound approach for multivariate equivalence testing.
  • Variability is effectively managed as a nuisance parameter.
  • The techniques are applicable to real-world pharmaceutical development challenges.

Conclusions:

  • The presented multivariate equivalence testing procedures offer a valuable extension to existing statistical methods.
  • These methods are particularly useful for demonstrating similarity in pharmaceutical manufacturing and development.
  • Comparative analysis of dissolution profiles serves as a practical demonstration of the methods' utility.